Prescription Drugs: Market Research Report

Date: July 22, 2009
Pages: 1810
Price:
US$ 3,950.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P3A41D04CB2EN
Leaflet:

Download PDF Leaflet

Prescription Drugs: Market Research Report
This report analyzes the worldwide markets for Prescription Drugs in US$ Billion by the following therapeutic class – Oncologics/ Cancer Drugs, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents, and Others.

The report provides separate comprehensive analytics for the US Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual forecasts are provided for each region for the period 2006 through 2015.

A five-year historic analysis is also provided for these markets.

The report profiles 292 companies including many key and niche players worldwide such as Abbott Laboratories, Allergan, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim Group, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Inc., Merck & Co. Inc., Merck Serono International S.A., Mylan, Inc., Novartis AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi-Aventis SA, Sanofi Pasteur, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Watson Pharmaceuticals, Inc., and Wyeth.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK

Pharma Industry Hit by Economic Downturn

Table 1. Worldwide Prescription Drugs Sales: 2006-2015 (includes corresponding Graph/Chart)

The Regional Impact
Emerging Markets to Drive Growth
Biotechnology
Biotech Bankruptcies Rife in the Current Economic Downturn
Economic Downturn Takes Toll on R&D
Outsourcing – A Mixed Bag
Generics – The Bright Spot

Table 2. Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2005 (In %) (includes corresponding Graph/Chart)
Table 3. Generics Share in Select Markets Worldwide – United States, Germany, UK, Spain, Japan, Italy, France, Finland, Denmark, The Netherlands, Norway, and Ireland (includes corresponding Graph/Chart)

Patent Expiries of Major Drugs: 2009-2012
Patient Spending
Operational Restructuring
Rising R&D Costs Call for Improved Efficiency
Concerns Over Drug Safety and Side Effects Impede Sales
Policy Issues Threaten Innovation
Regulatory Glitches and High Costs Hinder Biogeneric Growth
Opportunities Outside Drug Development
Going Forward in Forward Integration
Forward Integration into Diagnostics
Opportunities in Healthcare
Down the Distribution Chain

2. LEADING PHARMA COMPANIES AND DRUGS WORLDWIDE

Pfizer Reigns Supreme…

Table 4. Leading Global Pharmaceutical Companies Worldwide by Sales (2008, 2007, and 2006) - Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson & Johnson, Merck & Co., Abbott and Eli Lilly - in US$ Billion (includes corresponding Graph/Chart)

Leading Prescription Drugs Worldwide – Lipitor Leads the Way

Table 5. Leading Prescription Drugs Worldwide by Sales (2008, 2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel, Seroquel, Zyprexa, Remicade, Singulair and Levonox in US$ Billion (includes corresponding Graph/Chart)

Oncology Tops Therapeutic Classes

Table 6. Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and 2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others in US$ Billion (includes corresponding Graph/Chart)

3. THERAPEUTIC DRUG CLASSES

Cholesterol Reducers
Statins Lead the Way
Emerging Leaders

Table 7. Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes corresponding Graph/Chart)

Lack of Product Differentiation Mars Prospects
Zocor – The First Statin to Switch to OTC
Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond
Oncologics
Oncologics/ Cancer Drugs – Largest Therapeutic Class
High Unmet Needs to Drive Growth
Biologics to Reign Supreme
Leading Drugs
Leading Players
Novel Therapies
Respiratory Drugs
Leading Brands and Players

Table 8. Leading Asthma Drugs Worldwide – Value Sales for the Years 2004-2008 for Seretide, Singulair, Symbicort and Pulmicort (in US$ Billion) (includes corresponding Graph/Chart)
Table 9. Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US$ Billion) (includes corresponding Graph/Chart)

Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond
Antipsychotics
Leading Schizophrenia Drugs
Side Effects of Antipsychotics – A Major Issue
Patent Expiries
Patent Expiries of Leading Anti-Psychotic Drugs
Zyprexa Continues to Lose Market Share
Risperdal Sales to Plunge, Following its Patent Expiry
Generics - Yet to Make a Mark in Antipsychotics
Increasing Use of Antipsychotics in Children Raises Concerns
Proton Pump Inhibitors
Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond

Table 10. Leading Proton Pump Inhibitors Worldwide – Value Sales for the Years 2004 through 2006 (US$ Billion) - Nexium, Prevacid/Takepron, Protronix/Pantazol and AcipHex/Pariet (includes corresponding Graph/Chart)

Antidepressants
Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015
Erythropoietins
Competitive Landscape in the Global Erythropoietin Market
Leading Erythropoietin Drugs

Table 11. Leading Erythropoietin Drugs Worldwide – Annual Revenues for the Years 2004 through 2007 in US$ Billion for Aranesp, Procrit/Eprex, Epogen and NeoRecormon (includes corresponding Graph/Chart)

New and Pipeline Products
Biogenerics Pose Imminent Threat
Anti-Arthritics

Table 12. Leading Anti-arthritic Drugs Worldwide – Value Sales for Years 2006 through 2008 in US$ Billion - Enbrel, Remicade, Rituxan and Humira (includes corresponding Graph/Chart)

Anti-Epileptics
Disease Statistics
Available Drugs
Generics to Take the Lead in Anti-Epileptic Market

Table 13. Leading Anti-Epileptic Drugs Worldwide: Value Sales for years 2005 through 2007 in US$ Billion for Topamax, Lamictal, Depakote and Keppra (includes corresponding Graph/Chart)

Patent Expiries of Leading Anti-Epileptic Drugs
New Launches
Pipeline Drugs Bode Brighter Prospects
Pipeline Drugs in Antiepileptics
Calcium Channel Blockers
Antidiabetics

Table 14. Leading Anti-diabetic Drug Sales Worldwide: Value Sales for Years 2005 through 2008 in US$ Billion for Actos, Lantus, Avandia Franchise, Januivia and Byetta (includes corresponding Graph/Chart)

4. MARKET DYNAMICS

Pharma M&A Activity in 2008
Aggressive M&A Deals by Japanese Companies
Patent Expiries
Patent Expiries for 2008 and 2007
New Product Approvals

Table 15. New Drugs Approval from 2003-2008 (includes corresponding Graph/Chart)
Table 16. Biologics Approvals from 2003-2008 (includes corresponding Graph/Chart)
Table 17. Development of New Molecular Entities (Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods 1998-2002 & 2003-2007 (includes corresponding Graph/Chart)
Table 18. Number of Compounds Under Development by Country/Region: Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart)

New Molecular Entities (NMEs) Approved by FDA in 2008
New Biological Entities Approved by FDA in 2008
Research and Development

Table 19. R&D Investments by Pharmaceutical Sector in US and Europe: 2004-2007 (includes corresponding Graph/Chart)

Cost Pressures
R&D Productivity Slides Despite Increasing Investments
Aging Population Drives Demand

Table 20. World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart)

5. PRESCRIPTION PHARMACEUTICALS - AN OVERVIEW

Biologics
Evolution Of The Global Pharmaceutical Industry
Drug Development Process – FDA Perspective
Stages of Drug Development Process
Drug Discovery
Pre-Clinical Testing
Clinical Trials
Phase I Clinical Trial
Phase II Clinical Trial
Phase III Clinical Trial
New Drug Application
FDA Review
Phase IV Clinical Trials
FDA’s Drug Safety Review – The Global Standard

6. SELECT THERAPEUTIC CLASSES

Anti-arthritics
COX-2 Inhibitors
Antipsychotic Drugs
Anti-Ulcerants
Codeine & Combinations
Combination Drugs
Anti-Depressants
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs)
Serotonin Modulators (5-HT2 blockers)
Dopamine-norepinephrine Reuptake Inhibitors
Monoamine Oxidase Inhibitors (MAOIs)
Erythropoietin
Proton Pump Inhibitors
Seizure Disorder Drugs
Antihistamines
Calcium Channel Blockers
Cholesterol Reducers

7. MARKETING AND PROMOTIONS

Table 21. Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly, Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb (includes corresponding Graph/Chart)
Table 22. Promotional Spending through Professional Detailing by Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough and Wyeth (includes corresponding Graph/Chart)
Table 23. Direct-To-Consumer Promotional Spending By Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor, AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer Ingelheim and Eli Lilly (includes corresponding Graph/Chart)
Table 24. E-Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million – Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough, AstraZeneca and Sanofi- Aventis (includes corresponding Graph/Chart)

8. RECENT INDUSTRY ACTIVITY

Merck & Co. and Schering-Plough to Merge
Pfizer to Acquire Wyeth
CSL and Talecris Biotherapeutics to Withdraw Merger Agreement
AstraZeneca Partners with Merck to Analyze a New Combination of Anticancer Regimen
Sun Pharmaceutical Acquires Chattem
Novartis Acquires 25% Stake in Alcon
Takeda Acquires Millenium Pharmaceuticals
Teva Acquires Barr
Invitrogen and Applied Biosystems Merge
Eli Lilly Takes Over ImClone Systems
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy
Fresenius Acquires APP Pharmaceuticals
TPG Acquires 50% Stake in SIA International
GSK Acquires Sirtris
Shire Aquires Controlling Interest in Jerini
Boehringer Ingelheim to Purchase Actimis Pharmaceuticals
Sanofi Pasteur Acquires Acambis
Sanofi-Aventis Acquires Symbion
Nordic and Avista Acquires ConvaTec
King Pharmaceuticals Acquires Alpharma
Shionogi Acquires Sciele
Ranbaxy Inks Indian Marketing License for GLIADEL® with BioPro
Tibotec Gains EC Approval for PREZISTA®’s Extended Indication
GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines
AstraZeneca Obtains TRO for Generic Pulmicort Respules
Solvay Pharmaceuticals Enters Into a License Deal with Depomed
AstraZeneca Enters into an Agreement with Par Pharmaceutical
BioReliance and Provecs Enter into Agreement
Cornerstone BioPharma and Critical Therapeutics Merge to Form Cornerstone Therapeutics
GSK to Acquire Genelabs
Lpath and Merck Serono Forge Partnership
Allergan and Spectrum Ink Collaboration Deal for Bladder Cancer Drug
EMD Signs Licensing and Collaboration Deal with Theratechnologies
Medimetriks Receives License for Prescription Brands from Perrigo
Forest Partners with Phenomix for Developing Diabetic Drug
GSK Biologicals and AFFiRiS Sign Collaboration Agreement
Sanofi-Aventis Strengthens R&D Operations in the Chinese Market
UCB and Pfizer Establish Cyclofluidic
Valeant Pharmaceuticals Completes Coria Laboratories Acquisition
MedImmune Inks Agreement with Omninvest over Reverse Genetic Technology
Avidas Secures North American Rights of Crown’s Dermatology Products
Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline
Eli Lilly and Deciphera Enter into Collaboration and Licensing Deal
Roche, GlycArt and Genentech Sign Collaboration Agreement
Cardinal Health Plans to Spin-Off Medical and Clinical Products Businesses
Sanofi Pasteur Holding Acquires Acambis
Eisai Plans NDA Submission for Insomnia Drug
GlaxoSmithKline Enter into Strategic Alliance with Cellzome
Ablynx and Merck Serono Sign Nanobodies® Agreement
GlaxoSmithKline and Valeant Enter into Collaborative Agreement
Noven Enters Supply and License Agreements with P&G Pharmaceuticals
Eli Lilly Acquires SGX Pharmaceuticals
SymBio Pharmaceuticals Enters into a License Agreement with Eisai
Roche Sells Four Pharmaceutical Products to Meda AB
AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor
Gilead Sciences Inks Atripla®, HIV Drug Distribution Deal with Merck
Eisai China Enters into Licensing Deal with Health Vision
GSK and Harvard Stem Cell Institute Team Up for Drug Discovery
Teva Acquires Bentley Pharmaceuticals
Roche to Acquire ARIUS Research
GlaxoSmithKline and Actelion Collaborate
GSK Enters into Product Disinvestment Agreement with Aspen
Lupin Forges Marketing Alliance with ASCEND for Suprax® Tablets
Merck Serono Inks Multiple Sclerosis Drug-Development Deal with Bionomics
European Commission Approves Kuvan® of Merck Serono
GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs
Eli Lilly Announces Development & Licensing Agreement with TransPharma
Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO
Sepracor Acquires Oryx Pharmaceuticals
Mylan Takes Over Merck’s Outstanding Generics Operations
Gilead Acquires Cicletanine Business from Navitas
King Pharmaceuticals to License Third Opioid Analgesic Product
BioPhausia Acquires Prescription Pharmaceutical Offerings from AstraZeneca
Ranbaxy Enters into Strategic Product Development Agreement with Merck
EUSA Pharma Acquires Cytogen Corporation
Dr. Reddy’s Announces Two Major Acquisitions
EUSA Divests Stake in Antibody Research and Oncology Product to IDD
Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS
Ranbaxy Inks Strategic Business Alliance with Orchid
Pfizer Settles Patent Litigation for Lipitor with Ranbaxy
GSK Enters into Collaboration with Regulus Therapeutics
Janssen to Launch J&J Group’s New Drugs in Japan
Roche Alliance Partner Obtains Approval for Actemra in Japan
Abbott Receives Japanese Approval for Rheumatoid Arthritis Drug, HUMIRA®
Dr. Reddy’s Completes Acquisition of Jet Generici Srl
Eli Lilly, Transition Therapeutics Announce Licensing and Partnership Agreement
Dr. Reddy’s and 7TM Sign Drug Discovery Agreement for Selected Drug Targets
Endo Pharmaceuticals Obtains US Rights for Novartis’ Voltaren® Gel
Pfizer to Take Over Serenex
Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development Deal
AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel XR™
Forest, Mylan Amend Bystolic Agreement
Fujifilm to Acquire Stake in Toyama Chemicals
Graceway Takes Over Estrasorb
Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit
AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form Albireo
Cellegy to Merge with Adamis Pharmaceuticals
Mylan Reaches Accord with Novartis for Femara®’s Generic Product
Dyax Signs Licensing and Development Agreements with Sanofi-aventis
AstraZeneca Files for EU Approval of Seroquel XR™
MedImmune Files Biologics License Application for motavizumab to FDA
Farmavita, Belupo Sign Contract for Strategic Merger
Pfizer Japan Secures Production and Marketing Approval for Champix®
Eisai Enters into License Agreement with Abbott
Eisai Takes Over MGI Pharma
KV Pharmaceutical to Acquire Rights for Gestiva™ from Hologic
Forest and Novexel Enter into Licensing Agreement
Dr. Reddy’s Enters Settlement Agreement with Novartis for Exelon®
Taisho and Pfizer Sign Agreement for TS-032
Crucell Enters into Agreement with Sanofi Pasteur
EMEA Approves Second Biogeneric EPO, Retacrit
Endo Pharmaceuticals Licenses AZ-003 from Alexza
Schering-Plough and Centocor Modify Existing Distribution Agreement
GSK and Santaris Pharma Collaborate in RNA Antagonists Research
GSK Acquires Reliant Pharmaceuticals
Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/ Allergic Disease Agents
Bristol-Myers, Gilead Extend Agreement to Commercialize ATRIPLA® in Europe
GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell Research
GSK Allies with Galapagos for Antiviral and Antibacterial Development
Eisai and BioArctic Ink Licensing Deal for BAN2401
Biogen and Neurimmune Join Hands to Develop Drugs for Alzheimer's Disease
Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India
AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX® from FDA
Covance to Build High-Tech Drug Development Facility
Schering-Plough Takes Over Organon BioSciences
Takeda Launches Takeda San Francisco for Therapeutic Antibody Research
GSK to Disinvest Lotronex®
Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy
Watson Acquires Andrx
EPFL and Merck Serono Enter into Agreement
Acura and King R&D Sign Licensing Agreement for Opioid Analgesic Products
Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals
Wockhardt Takes Over Morton Grove Pharmaceuticals
GSK Enters into Collaboration with Tolerx for Development of Novel Therapies
Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan
Eli Lilly Announces Strategic Alliance with MacroGenics
BMS, ImClone, Merck Serono Sign Erbitux® Agreement
Wockhardt to Market Gnosis’ SAMe in India
Alpharma Grants US License for Ketoprofen in Transfersome® Gel to IDEA
Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR™
Synta and GSK Sign Oncology Molecule Development Collaboration
Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings
GSK Inks Antiviral and Antibacterial Drug Development Deal with Anacor
AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation
Mylan Takes over Merck Generics
Kissei and Eisai Ink Licensing Deal for Glufast® Tablets
AMRI Inaugurates New Research Unit in Hyderabad
Eisai Inks Co-Promotion Deal with Salix for COLAZAL® Capsules
Kowa and Teva to Establish Joint Venture Generic Drug Firm in Japan
Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical
Chugai and Teijin Sign Agreement for Co-Development of Anti-Diabetic Drug
MedImmune Inks Licensing Agreement with Novartis over Reverse Genetic Technology
EUSA Acquires Assets of Innocoll
Noven Enters Supply and License Agreements with P&G Pharmaceuticals
Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease
Noven Pharmaceuticals Acquires JDS Pharmaceuticals
HHS Places an Order with GSK for Bulk H5N1 Antigen
Synthon Completes Laboratorios Rider Acquisition
Targacept Forges Partnership with GSK
Dong Wha Signs Alliance with P&G Pharma to Develop Treatment Molecules for Osteoporosis
Barr and Gedeon Richter Sign Pact over Generic Version of LAMISIL®
Santarus and Victory Pharma Enter Into Co-Promotion Agreement
AMRI Enters into Collaboration for Research with Achaogen
SCI Collaborates with High Q Foundation for Research on Huntington’s Disease
MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals
Eli Lilly to Launch Public-Private Partnership for Drug Research in Tuberculosis
Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal
Strides Arcolab to Take Over Bio-Fermentation Facility in Italy
Amgen to Take Over Alantos Pharmaceuticals
GlaxoSmithKline Establishes R&D Center in China
Wockhardt Acquires Negma Laboratories
Eisai Inks Exclusive Agreement with Solstice over NeuroBloc®
Ranbaxy to Acquire Be-Tabs Pharmaceuticals
Pfizer Obtains Health Canada Approval for LIPITOR in Reducing Myocardial Infarction
GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted Infections
Bristol-Myers and Pfizer Ink Development and Commercialization Agreements
Cytos Biotechnology Grants Novartis with Global License for NicQb
Swiss Federal Register Adds ACOMPLIA® to Reimbursement List
Wockhardt to Introduce Syrio Pharma’s B-Lift Product Range in India
Eisai Acquires Morphotex
Ranbaxy Obtains Approval for RAN™ Cefprozil Formulations in Canada
Roche Partners with Transgene to Focus on Therapeutic Vaccine Program
Cardinal Health Divests Pharmaceutical Technologies and Services Segment to Blackstone Group
Roche to Acquire BioVeris Corporation
Eli Lilly Acquires Hypnion
Roche Takes Over THP, Broadens Antibody Research Facility
Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for TroVax®
Iroko Pharmaceuticals Acquires Rights to Indocin® and Aldomet® Products
Asahi Kasei Inks Licensing Agreement with Eisai Korea over Vasodilator Eril®
Merck Obtains EU Approval for JANUVIA™ Type 2 Diabetes Drug
Wockhardt Obtains FDA Approval for a Painkiller in the US
Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN®
GlaxoSmithKline Obtains FDA Approval for Tykerb®
Terapia Ranbaxy Secures Marketing Approvals for 20 New Products
Shionogi to Develop and Market BioCryst's peramivir in Japan
Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA® in Korea and Taiwan
Salix Acquires US Rights to Merck’s Two Oral Suspension Products
Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody Programs
GSK Commences Phase III Clinical Trials of Tykerb®, a Post-Operative Lapatinib
Roche Grants Glaxo with Exclusive Licensing Rights to its ‘Orlistat’ Drug
GSK and HGS Commence Phase III Trials of LymphoStat-B® in SLE
GSK and Fabre-Kramer Ink Global Deal for Gepirone ER
Ranbaxy Signs Agreement with Zenotech for Biosimilars’ Global Launch
Ranbaxy Inks Long-Term R&D Deal with GSK
Amgen Inks Three-year Aranesp Supply Agreement with Fresenius
AstraZeneca to Take Over Arrow Therapeutics
Eli Lilly Acquires ICOS Corporation
Pfizer Plans to Takeover BioRexis
Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX®
Eisai’s ‘Pariet®, 10mg Tablets’ Receive Clearance for New Indication in Japan
Eisai Receives EC Approval for Inovelon®
Pfizer Receives Marketing Authorization for Sutent® in European Union
GlaxoSmithKline Obtains Approval to Market Wellbutrin XR® in the Netherlands
Forest Laboratories Acquires US Biopharmaceutical Company, Cerexa
Mylan Laboratories Acquires 51.5% in Matrix
DUSA Enters into an Agreement with Daewoong Pharmaceutical
Penwest and Endo Amend Existing Contract on Opana® ER Collaboration
Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals
Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business
Ranbaxy Obtains FDA Approval for Atenolol Tablets
Gilead Sciences Acquires Myogen
Gilead Sciences Acquires Raylo Chemicals

9. FDA APPROVALS FOR 2009, 2008 AND 2007

10. A REVIEW OF SELECT PRODUCT INTRODUCTIONS IN THE PHARMA INDUSTRY

Amgen Receives Approval for Nplate(R)…
Takeda Wins FDA Marketing Approval for ULORIC…
Novartis and MMV Launch Coartem® Dispersible
Ipsen and Medicis Receives FDA Approval for Dysport…
Centocor Receives FDA Approval for Simponi…
Wyeth Receives FDA Approval for PRISTIQ™…
GSK Receives FDA Approval for Promacta®…
Cephalon Receives FDA Approval for TREANDA…
Adolor Receives FDA Approval For Entereg(R)…
Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets
Eisai US Receives FDA Approval for Banzel™ (Rufinamide)
Progenics Receives FDA Approval for RELISTOR…
J&J Receives Approval for Anti-HIV Medication ‘Intelence’…
Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US
Sandoz Introduces Eplerenone Tablets
Wockhardt Introduces Midazolam Injection in the US
Dr. Reddy’s Announces Launch of Generic Version of Imitrex® Tablets
Arbor Pharmaceuticals Debuts NEOTIC™ for Middle- Ear Infections
Promius Pharma Introduces EpiCeram® Emulsion
Sandoz Unveils Generic Variant of Imitrex® Injection
Dr. Reddy’s Launches Redihaler™ and Combihale™
Wyeth Launches Antihemophilic Factor, XYNTHA™
Bayer Schering Releases YAZ®
Mylan Introduces Nisoldipine ER Tablets in US
Ranbaxy Launches Generic Omeprazole in US
Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets
Teva Unveils Generic Equivalent of Lamictal® Tablets
Eisai and Helsinn Healthcare Introduce ALOXI® Injection for Prevention of PONV
Janssen and Patriot Unveil Authorized Generic Equivalent for Risperdal®
Watson Releases Generic Equivalent of MARINOL®
Sandoz Introduces Generic Form of Altace®
Abbott Introduces Aluvia® Tablet in South Africa
Dr. Reddy’s Rolls-out Atocor-R
Sandoz Unveils Generic Form of Maxipime®
Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA
Ranbaxy Pioneers Launch of New Bio-Generic Recombinant Osteoporosis Injection
Sandoz Introduces Generic Variant of Antizol® Injection
Sun Pharmaceuticals Introduces Injection of Amifostine
Sandoz Re-Launches Generic Form of Bactocill® Injection
Sandoz Introduces Generic Form of Cipro® Injection
Merck Serono Introduces Cyanokit® in Japanese Market
Ranbaxy Launches INERSAN Tablets in India and Nepal
Sandoz Launches Omnitrope™ Pen 5 with Liquid Cartridge
Endo Pharmaceuticals to Introduce OPANA® ER in Three Dosage Strengths
Sandoz Releases Generic Form of Camptosar®
Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets
Dr. Reddy’s Introduces Supanac®
Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets
GSK Announces FDA approval of Altabax™…
Novartis’ Tekturna HCT® Receives FDA Approval…
GSK Receives FDA Approval for Tykerb®…
Pfizer Receives FDA Approval for Selzentr…
Ortho-McNeil Receives Approval for DORIBAX™…
Merck Receives Approval for Isentress® …
BMS Wins FDA Approval for IXEMPRA™…
Novartis’ Tasigna® Receives FDA Approval…
Mylan Receives FDA Approval for Bystolic…
Roche’s Mircera Secures FDA Approval…
Eisai Launches New Dose Formulations of Aricept® Tablets in Japan
Chugai Launches Tarceva® Tablet in Japan
Sandoz Introduces Generic Version of Elocon® Lotion
Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada
Watson Unveils Tilia™ Fe
Ranbaxy Obtains Health Canada Approval for Ran®- Lisinopril Oral Tablets
Sandoz Releases Generic Form of Delestrogen® Injections
Sanofi and UCB Roll Out XYZAL® in US
Sandoz Expands Range of Generic Augmentin® Drugs
Sandoz Releases Generic Variant of Biaxin® for Oral Suspension
Sandoz Introduces Generic Form of Penlac® Topical Solution
Teva Releases Famciclovir Tablets
Ranbaxy Introduces Roliflo OD in India
Sandoz Introduces Generic Form of Toprol Xl® 50Mg Extended Release Tablet
Dr. Reddy’s Introduces Glimy MP1 and Glimy MP2
Sandoz Launches Approved Generic Equivalent of Lamisil®
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US
AstraZeneca Announces the Availability of Symbicort® pMDI
Chugai and Maruho Announce the Launch of Oxarol® Lotion
Ajinomoto and Eisai Jointly Launch ‘Actonel® 17. 5mg Tablets’
Sandoz Introduces Approved Generic Form of Lotrel®
Dr. Reddy’s Launches UltravexTM
Wockhardt Unveils Zolpidem Tablets in the US
Dr. Reddy’s Introduces Reditux™
Dr. Reddy’s Secures Approval for Launching Zolpidem Tartrate Tablets
Cipla Introduces Virenza Inhalation Capsules in India
Ranbaxy Introduces Osovair in India
GlaxoSmithKline Introduces Coreg CR™
Chugai Announces the Launch of Antiviral Agent, Copegus® Tablet
Ranbaxy Unveils Generic Atorvastatin in Denmark
Barr Unveils Generic ‘PROSCAR®’ Tablets
Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22. 5mg and 45mg
Barr Releases METAGLIP™ Tablets
SkinMedica Rolls Out Single-Dosage NeoBenz® Micro SD for Treating Acne
Teva Rolls Out Generic Equivalent of Wellbutrin XI® Tablets
Takeda Launches Takepron ® I.V for Injection 30mg
Takeda Launches duetact™ Combination Drug in USA
Teijin Pharma Launches Bonalon® Tablet for Treating Osteoporosis

11. FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Allergan, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca (UK)
Bayer AG (Germany)
Bristol-Myers Squibb (USA)
Boehringer Ingelheim Group (Germany)
Dr. Reddy's Laboratories Ltd. (India)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline Plc (UK)
Johnson & Johnson, Inc. (USA)
Merck & Co. Inc. (USA)
Merck Serono International S.A. (Switzerland)
Mylan, Inc. (USA)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Ranbaxy Laboratories Limited (India)
Sanofi-Aventis SA (France)
Sanofi Pasteur (France)
Takeda Pharmaceutical Company Limited (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
Watson Pharmaceuticals, Inc. (USA)
Wyeth (USA)

12. GLOBAL MARKET PERSPECTIVE

Table 25. World Recent Past, Current & Future Analysis for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 26. World Historic Review for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
Table 27. World 15-year Perspective for Prescription Drugs Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)
Table 28. World Recent Past, Current & Future Analysis for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 29. World Historic Review for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
Table 30. World 15-year Perspective for Prescription Pharmaceuticals Market by Therapeutic Class– Percentage Breakdown of Dollar Sales for Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. MARKET ANALYSIS

Generics in the US
Biologics Post Highest Growth
Leading Prescription Drugs in the US

Table 31. Leading Prescription Drugs in the US by Value Sales (2008) in US$ Billion - Lipitor, Nexium, Plavix, Advair Diskus, Seroquel, Singulair, Enbrel, Neulasta, Actos and Epogen (includes corresponding Graph/Chart)

Leading Therapeutic Classes in the US

Table 32. US Leading Therapeutic Classes by Revenue (2006-2008): Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Anteneo Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral Antiplatelets (in US$ Billion) (includes corresponding Graph/Chart)
Table 33. US Leading Therapeutic Classes by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Lipid Regulators, Codiene & Combinations, Anti-Depressants, Ace Inhibitors, Beta Blockers, Proton Pump Inhibitors, Seizure Disorders, Synthetic Thyroid Hormones, Calcium Blockers, Benzodiazepines, and Others (includes corresponding Graph/Chart)

Leading Players

Table 34. Leading Companies in the US Pharmaceutical Market (2006-2008): Percentage Breakdown of Value Sales for Pfizer, GlaxoSmithKline, Merck & Co., Johnson & Johnson, AstraZeneca, Amgen, Novartis, Hoffman-La Roche, Sanofi-Aventis, Eli Lilly and Others (includes corresponding Graph/Chart)
Table 35. US Pharmaceutical Market (2006-2008): Percentage Breakdown of Dispensed Prescriptions for Teva Pharmaceuticals, Mylan Laboratories, Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co., Mallinckrodt, Apotex, Qualitest, and Others (includes corresponding Graph/Chart)

Prescription Drug Spending

Table 36. Healthcare Spending in the US by Sector (2006) (includes corresponding Graph/Chart)

Increasing Share of Government in Prescription Drug Spending

Table 37. US Prescription Pharmaceutical Industry (2005 and 2006): Percentage Breakdown of Prescription Pharmaceutical Spending by Source for Private Insurance, Medicare, Medicaid, Out-of-Pocket and Other Public Spending (includes corresponding Graph/Chart)

Medicare Part D
Drug Price Regulations in the US
Pharmaceutical Marketing – A High Investment Area in the US

Table 38. Pharmaceutical Promotional Spending in the US by Type (2006-2008): Professionals-Directed Promotions and Consumer-Directed Promotions (in US$ Billion) (includes corresponding Graph/Chart)

Major Distribution Channels

Table 39. Major Prescription Drugs’ Distribution Channels in the US by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Chain Stores, Independent Stores, Food Stores, Long-term Care, and Mail Order (includes corresponding Graph/Chart)
Table 40. Major Prescription Drugs’ Distribution Channels in the US by Value Sakes (2006-2008): Percentage Breakdown for Distribution Channel for Chain Stores, Mail Order, Independent Stores, Clinics, Non-government Hospitals, Food Stores and Other Channels (includes corresponding Graph/Chart)

Fewer Product Launches
Generic Penetration and PBMs Moderate Prescription Drug Price Growth
Co-payment Differentials to Increase Generic Substitution
High Prescription Drug Costs Drive Drug Re- Importation
Direct-to-Consumer Advertising
The 2006 Revision of Package Insert Format
Other Initiatives
Role of PBMs in the Pharmaceutical Supply Chain
Prescription Drug Pricing in US
Role of Mail-Order Pharmacies in Cost Containment
Product Launches
Strategic Corporate Developments
Select Key Players

B. MARKET ANALYTICS

Table 41. US Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 42. US Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
Table 43. US Recent Past, Current & Future Analysis for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 44. US Historic Review for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)
Table 45. US 15-Year Perspective for Prescription Pharmaceuticals by Therapeutic Class – Percentage Breakdown of Dollar Sales for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart)

2. CANADA

A. MARKET ANALYSIS

Current and Future Analysis
Leading Drugs

Table 46. Leading Prescription Drugs in Canada in Terms of Number of Dispensed Prescriptions (2006 and 2007) in Million Scripts: Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa, Novo-Venlafaxine XR and Apo- Furosemide (includes corresponding Graph/Chart)

Major Therapeutic Classes

Table 47. Leading Therapeutic Classes in Canada in terms of Dispensed Prescription (2006 and 2007): Percentage Breakdown of Cardiovascular, Antipsychotics, Gastrointestinal/Genitourinary, Lipid Regulators, Hormones, Systemic Anti-infective, Analgesics, Diabetes Therapy, Diuretics, Neurological Disorders and Others (includes corresponding Graph/Chart)

Prescription Drugs Spending on the Rise
Private Sector Insurance Continues to Gain Popularity
Canadian Prescription Drugs Market- A Comparison with the US
Generic Sales to Outpace Branded Drugs Sales
Generics Market in Canada
Generics to Offer Potential Cost Savings
New Patented Drugs- Adding Costs but Little Value
Two-level Drug Approval Process in Canada
Policy Differences Affect Generic Substitution Among Provinces
Applied and Other Research Take Major Chunk of R&D Investments in Canada

Table 48. Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research, Basic Research and Other Research Areas (includes corresponding Graph/Chart)

Product Launches
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 49. Canadian Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 50. Canadian Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

3. JAPAN

A. MARKET ANALYSIS

Current and Future Analysis
Generics Promotion in Japan
Ageing Population – A Prime Target
Competitive Landscape

Table 51. Leading Pharmaceutical Companies in Japan (2008): Percentage Breakdown of Revenues for Takeda Pharmaceuticals, Astellas Seiyaku, Dai-ichi Sankyo, Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai, GlaxoSmithKline and Otsuka Seiyaku (includes corresponding Graph/Chart)
Table 52. Leading Prescription Drugs in Japan (2006 and 2007): Value Sales in US$ Million for Blopress, Diovan, Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin, Micardis and Amlodin (includes corresponding Graph/Chart)

Cancer Drugs to Witness Robust Growth
Biennial Price Reduction to Impact Markets of Key Therapeutic Classes
Product Launches
Strategic Corporate Developments
Select Key Players

B. MARKET ANALYTICS

Table 53. Japanese Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 54. Japanese Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

4. EUROPE

A. MARKET ANALYSIS

Current and Future Analysis
Pharmaceutical Spending on the Rise
Mounting Healthcare Bills Boost Generic Drugs Consumption
Biogenerics Foray into Europe
SNRIs Likely to Replace SSRIs
Research and Development

Table 55. European Investments in Pharma Research & Development: 2005-2007 (includes corresponding Graph/Chart)

Europe - The Research and Production Hub for Vaccines Worldwide
Parallel Trade in Europe
New Rules to Offer Respite to Parallel Traders
Manufacturers Seek Greater Control Over Supply Chain
Pharmaceutical Industry Overview In Select Countries
France
Germany
Generics
Exports
Production
Prices
New Molecular Entities
R&D Investments
Parallel trade
Genetically Manufactured Drugs

Table 56. German Genetically Manufactured Pharmaceuticals (2007): Percentage Breakdown of Sales by Type - Vaccines, Insulins, Interferons, Monoclonal Antibodies, Erythropoietin, and Others (includes corresponding Graph/Chart)

United Kingdom
Spain
Cost Containment Efforts
Increased Promotion for Generics
Re-launch of Reference Price System
Distribution
Italy
Generics Gain Traction
Sweden
Greece
Unique Pricing Model for Drugs
Product Launches
Strategic Corporate Developments
Select Key Players

B. MARKET ANALYTICS

Table 57. European Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 58. European Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. MARKET ANALYSIS

Current and Future Analysis
Overview of Pharmaceutical Industries in Select Countries
India
Competitive Advantage
Number of FDA Approved Plants in India Vis-à-Vis Other Countries
Increasing Disposable Income Driving Consumption of Drugs
Generics to Surge Growth in Exports
Manufacturers Continue to Target Developed Markets
India to Emerge as an Important Pharmaceutical Manufacturing Center
Threat from Other Asian Countries
India to Emerge as a Major Hub for Biogenerics
Acute Therapy Class Leads the Market

Table 59. Leading Therapeutic Categories in the Indian Pharmaceutical Industry- Percentage Share Breakdown of Value Sales for Anti-infectives, Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins, Analgesics, Women’s Health, Central Nervous System, Dermatology, and Others (includes corresponding Graph/Chart)

Increase in Private Healthcare Services
China
Chinese Pharma Industry Remains Immune to Global Crisis, for Now
Issues and Trends
Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare System
Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to Lead
Generics in China
Traditional Medicines – Substantial Share

Table 60. Leading Medicine Types in China (2005): Percentage share for Allopathic Medicines, Traditional Chinese Medicines (TCM), and Other Drugs (includes corresponding Graph/Chart)

Underserved Markets Prompt Government to Foster Development
Domestic EPO Market Booming, Domestic Players Continue their Domination
Chinese Antipsychotics Market to Witness Substantial Growth
Antidepressant Drugs to Exhibit Robust Sales
Indonesia
Market Features
Government-Enforced Pricing Control Over Essential Drugs
Distribution
Korea
Patent Expiries of Leading Drugs in South Korea: 2008 and 2009
Malaysia
Foreign Investments on the Rise
Domestic Market
Australia
Pharmaceutical Benefits Scheme
Government’s Industry Development Programs
Outlook
Product Launches
Strategic Corporate Developments
Select Key Players

B. MARKET ANALYTICS

Table 61. Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 62. Asia-Pacific Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

6. LATIN AMERICA

A. MARKET ANALYSIS

Current and Future Analysis
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 63. Latin American Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 64. Latin American Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

7. REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis
Product Launches
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 65. Rest of World Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 66. Rest of World Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 292 (including Divisions/Subsidiaries - 360)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Latin America
Africa
Skip to top


Ask Your Question

Prescription Drugs: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: